IRIDEX Reports Slight Revenue Decline in Q1 Fiscal Year 2026

IRIDEX Corporation reported a slight decline in financial performance for the first quarter of fiscal year 2026, with total revenues of $11.8 million, down 0.8% from $11.9 million in the same period last year. The company experienced a decrease in gross profit, which fell to $4.7 million from $5.0 million, resulting in a gross margin of 40.2%, down from 42.5%. The decline in gross margin was attributed to higher manufacturing costs and increased product costs due to recent tariff developments. The net loss for the quarter was $524,000, or $(0.03) per share, an improvement compared to a net loss of $1.7 million, or $(0.10) per share, in the prior year.

In terms of operational metrics, IRIDEX's revenue from its glaucoma product line, particularly the Cyclo G6 laser system, increased by 14.5% to $3.6 million. However, revenue from the retina product line decreased by 12.3% to $5.8 million, which contributed to the overall revenue decline. The company’s sales and marketing expenses remained stable at $2.5 million, while general and administrative expenses decreased by 16% to $1.6 million, reflecting cost-saving initiatives. Research and development expenses were flat at $0.9 million, indicating a focus on maintaining existing product lines rather than expanding new investments.

IRIDEX continues to navigate a challenging macroeconomic environment, which has affected capital equipment purchasing decisions among hospitals and surgical centers. The company noted that geopolitical uncertainties, including conflicts in the Middle East and trade tensions, have led to extended purchase decision cycles among customers. Despite these challenges, IRIDEX remains committed to its strategic partnership with Topcon Corporation, which serves as an exclusive distributor for certain international markets, and continues to explore opportunities for geographic expansion.

As of April 4, 2026, IRIDEX had cash and cash equivalents of $4.6 million, down from $6.0 million at the beginning of the fiscal year. The company reported net cash used in operating activities of $1.3 million for the quarter, compared to $1.1 million in the same period last year. Looking ahead, IRIDEX believes its existing cash reserves will be sufficient to meet anticipated cash needs over the next 12 months, although it acknowledges that future capital requirements will depend on various factors, including growth rates and the timing of new product introductions. The company remains cautious about its ability to raise additional financing on favorable terms, which could impact its growth and operational strategies.